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Introduction {#acn351002-sec-0005}
============

Neuromuscular diseases impair voluntary movement by affecting structure or function of the motor unit. Over 500 genes are associated with Mendelian neuromuscular diseases.[1](#acn351002-bib-0001){ref-type="ref"} Genetic diagnosis informs prognosis, allows carrier‐ and familial‐screening, and enables evidence‐based treatment. In 2012, a collaboration between the Neurogenetic Diseases Group (Harry Perkins Institute of Medical Research), the Department of Diagnostic Genomics (PathWest), and the Lotterywest State Bioinformatics Facility Genomics (LSBFG) designed a comprehensive panel that included all known neuromuscular disease genes that were amenable to sequencing with NGS. The panel became widely ordered by clinicians across Australia and New Zealand, and effectively became the *de facto* standard of care for Australasia. The panel was also used for investigating patients with apparently novel neuromuscular phenotypes on a research basis. Here we present findings from the analysis of \>2200 patients (both diagnostic and research) on these comprehensive neuromuscular disease gene panels.

Materials and Methods {#acn351002-sec-0006}
=====================

Panel design {#acn351002-sec-0007}
------------

### Version 1 {#acn351002-sec-0008}

The panel included genes from the 2012 Neuromuscular Disorders Gene Table[2](#acn351002-bib-0002){ref-type="ref"} with pathogenic variants detectable by NGS (*n* = 245), unpublished candidate disease genes (*n* = 23), and cardiomyopathy disease genes (*n* = 59). Cardiomyopathy genes were included due to the overlap of skeletal muscle diseases with associated cardiomyopathy and to avoid needing two panels. Overall, 336 genes were targeted. Unpublished candidate disease genes were selected based on discussion with world experts.

### Version 2 {#acn351002-sec-0009}

In 2014, 193 new disease genes were added from the 2014 Neuromuscular Disorders Gene Table.[3](#acn351002-bib-0003){ref-type="ref"} Candidate disease genes with no diagnostic yield on Version 1 were removed. Cardiac genes that were not relevant for neuromuscular diseases were removed. There were 464 genes on Version 2. The clinical disease groupings and their associated genes for Version 1 and Version 2 are provided in Table [S1](#acn351002-sup-0001){ref-type="supplementary-material"}.

Sequencing {#acn351002-sec-0010}
----------

Ion Torrent Proton sequencing (Life Technologies) was performed at LSBFG using NEB NeXT Ultra (New England Biosciences) and Ion Xpress Barcode Adapters with T‐overhangs, and Ion TargetSeq Custom Enrichment Kits (Life Technologies). Positive control samples were selected from an archived cohort at Diagnostic Genomics. For Version 1, 32 controls were sequenced: 20 patients with known small‐scale variants (e.g., single nucleotide variants) and 12 patients with known copy number variants (CNVs). This was partly to determine the optimal number of samples per chip. Target coverage analysis was performed with BedTools.[4](#acn351002-bib-0004){ref-type="ref"} For Version 2, a verification rather than full validation was performed as sequencing was already optimized. Additional probes were added to provide deeper sequencing of known low‐coverage areas from Version 1 (Table [S2](#acn351002-sup-0002){ref-type="supplementary-material"}). Therefore, running a number of positive control samples during the first sequencing runs was not required. Instead, an identical control DNA sample was sequenced on every run for Version 2 as a benchmarking sample.

Variant calling, annotation, analysis, and validation {#acn351002-sec-0011}
-----------------------------------------------------

Base calling, mapping, and variant calling were performed using Torrent Suite 3.6.2 or 4.2 with high stringency settings (GRCh37). In the diagnostic setting, Cartagenia BenchLab software (Agilent Technologies) was used for annotation and analysis. Research samples were annotated using ANNOVAR,[4](#acn351002-bib-0004){ref-type="ref"} as previously described.[5](#acn351002-bib-0005){ref-type="ref"} In the diagnostic setting, bioinformatic filters were used as a first pass to restrict analysis to a subpanel of genes associated with each clinical phenotype. If no pathogenic variant was identified, the entire panel was analyzed. Variants with a minor allele frequency of \>2% were bioinformatically filtered from analysis.

For this study, a CNV was defined as ≥50 nucleotides, whereas a "small indel" was \<50 nucleotides.[6](#acn351002-bib-0006){ref-type="ref"} For quantification of variant subtypes, "truncating" included frameshift, start loss, and stop gain variants. Splicing variants were allocated into a separate category because their effects are difficult to predict without functional data.

Due to the high sequencing read‐depth obtained with the panel, it was possible to identify CNVs ranging from one exon to entire genes by calculating large deviations in read depth. For each sequencing run, the read depth per exon was normalized at 1. If read depth per exon exceeded two standard deviations from the normalized read depth, it was flagged as a possible CNV (i.e., close to 0.5 for heterozygous deletion or 1.5 for heterozygous duplication). Validation of this method was performed on 12 positive control samples (Table [S3](#acn351002-sup-0003){ref-type="supplementary-material"}). CNVs were confirmed using appropriate Sanger[7](#acn351002-bib-0007){ref-type="ref"}‐based sequencing approaches or multiplex ligation‐dependent probe amplification (MLPA)[8](#acn351002-bib-0008){ref-type="ref"} depending on size. The diagnostic laboratory adopted the American College of Medical Genetics (ACMG) guidelines to classify variants when they became available in 2015.[9](#acn351002-bib-0009){ref-type="ref"} Variants were only reported as pathogenic if they were classified as class 4 (likely pathogenic) or class 5 (pathogenic).[9](#acn351002-bib-0009){ref-type="ref"} Variants of class 3 or lower were not reported as pathogenic. Segregation studies were rarely feasible due to the absence of familial DNA, with the exception of de novo variants in pediatric patients. The research laboratory was able to interpret variants on a research‐only basis, as it was not accredited by the National Association of Testing Authorities, Australia (NATA). If a likely class 4 or class 5 variant was found, interpretation was referred to Diagnostic Genomics for validation in the NATA‐accredited laboratory. Sanger sequencing[7](#acn351002-bib-0007){ref-type="ref"} was used to validate putative missense/small indels.

Cohort {#acn351002-sec-0012}
------

Many patients analyzed on Version 1 were already known to Diagnostic Genomics (DNA samples stored from as far back as 1989), as opposed to truly "prospective" samples. Diagnostic panel requests were accepted from neurologists, clinical geneticists, pediatricians, and other appropriate specialists. Research panel requests were undertaken on a collaborative basis with the Neurogenetic Diseases Group. If multiple members of the same family were sequenced, only the proband was included in the present analysis. The clinical and pedigree information provided by the requesting clinician was highly variable, ranging from meticulous to single words (e.g., "weakness"). Age of onset was typically unavailable. We instead used patient age at first sample submission to Diagnostic Genomics ("patient age at referral" or "PAR") as a proxy. Details of prior single gene testing were almost always unavailable, so this was excluded from the study.

Clinical correlation {#acn351002-sec-0013}
--------------------

We measured which disease groups and genes had the best concordance between the original clinical diagnosis and the genetic diagnosis ("clinical correlation"; e.g., a patient clinically determined to have LGMD has a causative variant in a LGMD associated gene).[10](#acn351002-bib-0010){ref-type="ref"} Clinical categories with \<5 patients, and genes with \<5 reports issued were excluded from this analysis to prevent skewed analysis due to small sample size.

Statistical analysis {#acn351002-sec-0014}
--------------------

Statistical analysis was performed with IBM SPSS Statistics (IBM Corp. Released 2015. IBM SPSS Statistics for Macintosh, Version 23.0. Armonk, NY: IBM Corp). The chi‐square test of homogeneity was used to assess interversion differences between diagnostic success and clinical correlation. We calculated the mean difference in age between solved and unsolved patients using a Welch *t*‐test. Correlation between PAR and diagnostic success was assessed using Pearson\'s product‐moment correlation. Due to the low number of patients aged 70 years or older, these data points were collapsed into a single bin of "≥70 years." A scatter plot of diagnostic success (Fig. [1](#acn351002-fig-0001){ref-type="fig"}) was generated using GraphPad Prism version 8.0.0 for Macintosh (GraphPad Software, San Diego, CA, <http://www.graphpad.com>).

![Diagnostic success percentage by patient age at referral. Due to the low number of patients past the age of 70, diagnostic success for patients 70 or greater was collapsed into one bin. Pearson's correlation coefficient was − 0.561, *P* = 0.0004. This indicates a statistically significant, moderately negative correlation between diagnostic success and age.](ACN3-7-353-g001){#acn351002-fig-0001}

Results {#acn351002-sec-0015}
=======

Panel validation {#acn351002-sec-0016}
----------------

The average sequencing depth was 309‐fold (\>96% target regions ≥20‐fold depth). Positive controls on Version 1 achieved a 90.0% success rate (18/20) for small‐scale variants (Table [S3](#acn351002-sup-0003){ref-type="supplementary-material"}). In the two unsuccessful controls, one variant was in a poorly coverage region, and the other in a homopolymer region, which in our experience sequence poorly on the Proton platform. Version 1 CNV controls achieved a 91.6% success rate (11/12). The failed sample had a *PAFAH1B1* exon 3 deletion, which was called as deletion of exons 2--4. The optimal number of samples per chip was 16. For Version 2, improved coverage of known gaps from Version 1 was evident from analysis of the benchmarking sample from each run. Each chip still used 16 samples per run.

Turnaround time and cost {#acn351002-sec-0017}
------------------------

The typical turnaround time for sample processing, sequencing, analysis, and report issuing was 12 weeks. However, this timeframe was highly variable, depending on the need for further clinical information or functional testing. In urgent prenatal or perinatal cases where a genetic diagnosis could immediately inform care, a 2‐week turnaround time could be achieved. Sample cost was AUD1000 (USD730 based on December 31st 2015 exchange rate) per patient, which included expert analysis and diagnostic reporting.

Cohort description {#acn351002-sec-0018}
------------------

Overall, 2249 patients were analyzed (56% (1261) male; 42% (937) female; 2% (51) sex not specified; 1054 Version 1; 1195 Version 2). Patient number per clinical disease grouping is shown in Table [1](#acn351002-tbl-0001){ref-type="table"}. The mean PAR was 30.6 years (range 0--91). The mean PAR was significantly lower in the solved population compared to unsolved (solved mean 26.4 SD ± 21.4 years; unsolved mean 32.5 SD ± 24.0 years; mean difference 6.1 SD ± 1.0, 95% years, CI 4.1--8.2, *P* = 4.6326E‐9). There was a moderately negative correlation between PAR and diagnostic success (*r* = −0.54, *P* = 3.4512E‐164) with PAR explaining 30% of the variation in diagnostic success (see Fig. [1](#acn351002-fig-0001){ref-type="fig"}). Only 2/25 patients received a genetic diagnosis past the age of 80 years (8% success). The oldest was 83 years, with a peripheral nerve disorder caused by a *BSCL2* pathogenic variant.

###### 

Summary table of diagnostic outcomes.

  Clinical disease category                 Percentage diagnosed   Inheritance pattern percentage in solved patients (V1 and V2)   Percentage clinical correlation in solved patients (V1 and V2)               
  ----------------------------------------- ---------------------- --------------------------------------------------------------- ---------------------------------------------------------------- ----- ----- -----
  Anterior horn cell *n* = 82               8% (3/37)\*            33% (15/45)\*                                                   39%                                                              61%   0%    39%
  Ataxia *n* = 108                          41% (14/34)\*          18% (14/74)\*                                                   36%                                                              64%   0%    57%
  Channelopathy *n* = 104                   36% (20/56)            50% (24/48)                                                     64%                                                              36%   0%    81%
  Congenital myasthenic syndrome *n* = 37   24% (5/21)             44% (7/16)                                                      18%                                                              82%   0%    64%
  Congenital myopathy *n* = 145             43% (34/80)            32% (21/65)                                                     55%                                                              42%   4%    95%
  Distal arthrogryposis *n* = 116           29% (18/63)            28% (15/53)                                                     59%                                                              41%   0%    72%
  Distal myopathy *n* = 45                  35% (9/26)             18% (4/22)                                                      62%                                                              38%   0%    54%
  Dystonia *n* = 45                         N/A                    26% (11/43)                                                     73%                                                              18%   9%    91%
  Hereditary spastic paraplegia *n* = 225   36% (36/99)            29% (37/126)                                                    62%                                                              36%   3%    95%
  Metabolic muscular *n* = 222              24% (32/137)           17% (14/85)                                                     35%                                                              59%   7%    80%
  Metabolic neurological *n* = 20           0.0% (0/1)             10% (2/19)                                                      50%                                                              50%   0%    N/A
  Miscellaneous *n* = 57                    46% (11/24)            21% (7/33)                                                      50%                                                              39%   11%   N/A
  Mitochondrial *n* = 22                    17% (1/6)              25% (4/16)                                                      40%                                                              60%   0%    60%
  Muscular dystrophy *n* = 656              35% (114/323)          34% (112/333)                                                   36%                                                              47%   17%   93%
  Peripheral nerve disorder *n* = 347       27% (38/142)           23% (47/205)                                                    64%                                                              26%   11%   82%
  Overall                                   32%\*                  28%\*                                                           46%                                                              45%   9%    74%

Summary table of diagnostic success across several key variables, split by clinical disease category. Groups annotated with an asterisk (\*) denote a statistically significant change. N/A, not applicable.

John Wiley & Sons, Ltd

Diagnostic outcomes and trends {#acn351002-sec-0019}
------------------------------

In total, 665 patients received a genetic diagnosis (overall diagnostic rate 30%). On Version 1, 32% of patients received a genetic diagnosis, which decreased to 28% on Version 2 (proportion decrease 0.04, *P* = 0.004). However, if genes only present on Version 2 were excluded, the diagnostic rate decreased to 26%. Missense pathogenic variants were the most frequently reported in our cohort (57%), followed by truncating (27%), splicing (8%), small indels (3%), and CNVs (4%). The diagnostic success rate for anterior horn cell (AHC) disease increased from 8% to 33% between Versions 1 and 2 (proportion increase 0.252, *P* = 0.006). The diagnostic success for ataxia decreased from 41% to 18% (proportion decrease 0.223, *P* = 0.01). The diagnostic success rate of research samples sharply decreased from 26% to 9% (*P* = 0.0006) on Version 2. Success of diagnostic samples also decreased from 34% to 28% (*P* = 0.002). Channelopathies had the highest overall diagnostic success rate at 42%. Metabolic neurological disorders had the lowest at 10% (Table [1](#acn351002-tbl-0001){ref-type="table"}). Information for all solved and unsolved patients can be found in Tables [S4](#acn351002-sup-0004){ref-type="supplementary-material"} and [S5](#acn351002-sup-0005){ref-type="supplementary-material"}, respectively.

The top 10 most frequently reported genes accounted for 38% of diagnoses (Table [2](#acn351002-tbl-0002){ref-type="table"}). For many disease categories, a small number of genes were responsible for the majority of disease burden (Table [3](#acn351002-tbl-0003){ref-type="table"}). Diagnoses were made in 35% (136/390) of all genes (i.e., combination of Version 1 and Version 2). Of the new genes added to Version 2, 30/193 had diagnostic reports issued (16% of the new additions; 22% of total reported genes).

###### 

Most frequently reported disease genes.

  Gene       Count   Percent
  ---------- ------- ---------
  *RYR1*     49      7.3%
  *DMD*      39      5.8%
  *SPG7*     32      4.8%
  *SPAST*    25      3.7%
  *TTN*      23      3.4%
  *CLCN1*    22      3.3%
  *CAPN3*    20      3.0%
  *COL6A1*   16      2.4%
  *FKRP*     16      2.4%
  *NEB*      15      2.2%

List of the 10 genes that caused disease in the highest percentage of patients. These 10 genes harbored 38% of the pathogenic diagnostic reports in our cohort.

John Wiley & Sons, Ltd

###### 

High contribution disease genes.

  Clinical disease group   Gene      Count   Percent of category
  ------------------------ --------- ------- ---------------------
  Ataxia                   *SPG7*    11      39.3%
  *SACS*                   3         10.7%   
  Channelopathy            *CLCN1*   22      48.9%
  *SCN4A*                  13        28.9%   
  Dystonia                 *GCH1*    3       27.3%
  *ATP1A3*                 2         18.2%   
  *TOR1A*                  2         18.2%   
  HSP                      *SPAST*   22      30.1%
  *SPG7*                   21        28.8%   
  Metabolic muscle         *RYR1*    16      34%
  PYGM                     6         12.8%   

List of the highest contributing genes in clinical categories that had a small number of genes explain a large proportion of disease burden.

John Wiley & Sons, Ltd

Most pathogenic variants were seen on only one allele (60%), 19% on two alleles, and 21% three or more alleles. The four most common pathogenic variants comprised 8.7% of all disease alleles, namely: *SPG7*: c.1529C\>T, p.Ala510Val (*n* = 35 alleles; 3.8% of disease alleles), followed by *FKRP*: c.826C\>A, p.Leu276Ile (*n* = 26 alleles; 2.8% of disease alleles), *ANO5*: c.191dupA, p.Asn64*fs* and *SH3TC2*: c.2860C\>T, p.Arg954\* (both *n* = 10 alleles; 1.1% of disease alleles).

The disease groupings with the highest clinical correlation were hereditary spastic paraplegia ((HSP) 95%), muscular dystrophy (93%), dystonia, and congenital myopathy (both 91%). The category with the lowest correlation was AHC disease, with 50%. Mean clinical correlation was 74% (Table [1](#acn351002-tbl-0001){ref-type="table"}). Fourteen genes had 100% clinical correlation (Table [4](#acn351002-tbl-0004){ref-type="table"}).

###### 

Clinical correlation percentage in genes with 5+ reports issued.

  ---------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  91--100%   *ACTA1, CAPN3, CLCN1* [\*](#acn351002-note-0007){ref-type="fn"} *, COL6A1* [\*](#acn351002-note-0007){ref-type="fn"} *, COL6A2* [\*](#acn351002-note-0007){ref-type="fn"} *, COL6A3* [\*](#acn351002-note-0007){ref-type="fn"} *, DMD, DYSF* [\*](#acn351002-note-0007){ref-type="fn"} *, GJB1* [\*](#acn351002-note-0007){ref-type="fn"} *, KIF5A* [\*](#acn351002-note-0007){ref-type="fn"} *, MTM1* [\*](#acn351002-note-0007){ref-type="fn"} *, NEB* [\*](#acn351002-note-0007){ref-type="fn"} *, PMP22* [\*](#acn351002-note-0007){ref-type="fn"} *, PYGM* [\*](#acn351002-note-0007){ref-type="fn"} *, REEP1* [\*](#acn351002-note-0007){ref-type="fn"} *, SCN4A, SGCB* [\*](#acn351002-note-0007){ref-type="fn"} *, SH3TC2* [\*](#acn351002-note-0007){ref-type="fn"} *, SPAST, TTN*
  81--90%    *LMNA, MPZ, FKRP, LAMA2, RYR1, TRPV4, SPG7*
  71--80%    *GMPPB, KIF1A, MYH7, POMT1, ANO5, SGCA, TPM2*
  61--70%    *MFN2, IGHMBP2*
  51--60     *CACNA1A, CPT2, SACS*
  \<50%      *SEPN1, DYNC1H1* [[†]{.smallcaps}](#acn351002-note-0008){ref-type="fn"}
  ---------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Clinical correlation percentages for genes with five or more diagnostic reports issued.

Indicates 100%.

Indicates 0%.

John Wiley & Sons, Ltd

Often, patients were "diagnosed by sequencing" where the genetic diagnosis clarified the clinical diagnosis. Pathogenic variants in *SACS* were found in four patients diagnosed with a nerve disorder, one diagnosed with distal arthrogryposis, and one diagnosed with muscular dystrophy. An infant diagnosed with a neurogenic disorder had a pathogenic variant in *ACTA1*. Two patients (aged 51 and 67 years) diagnosed with muscular dystrophy had a pathogenic *ACTA1* variant. Three patients diagnosed with AHC disease had pathogenic variants in *RYR1*, and two had pathogenic variants in *FKRP*. Pathogenic *SOD1* variants were found in two patients diagnosed with neurogenic disorders, and one diagnosed with muscular dystrophy. Multiple phenotypic expansions were identified; some have been published.[5](#acn351002-bib-0005){ref-type="ref"}, [11](#acn351002-bib-0011){ref-type="ref"}, [12](#acn351002-bib-0012){ref-type="ref"}, [13](#acn351002-bib-0013){ref-type="ref"}, [14](#acn351002-bib-0014){ref-type="ref"}

Discussion {#acn351002-sec-0020}
==========

Disease features and laboratory findings are often nonspecific in neuromuscular diseases, particularly early or late in disease progression.[15](#acn351002-bib-0015){ref-type="ref"}, [16](#acn351002-bib-0016){ref-type="ref"} A comprehensive gene panel is especially useful for heterogeneous diseases as it facilitates diagnosis despite uncertain disease etiology or atypical presentation, and can partly compensate for variable levels of clinical acumen/assessment and/or limited clinical information.[10](#acn351002-bib-0010){ref-type="ref"}, [17](#acn351002-bib-0017){ref-type="ref"}, [18](#acn351002-bib-0018){ref-type="ref"}, [19](#acn351002-bib-0019){ref-type="ref"} However, detailed clinical information should guide genetic diagnosis and reduce turnaround time. Genetic testing does not replace clinical workup.

Neuromuscular diseases are also highly genetically heterogeneous. A comprehensive panel facilitates phenotypic expansions by allowing analysis of genes that would not have been chosen as candidates based on the clinical presentation. Our cohort provided several published examples*.* [5](#acn351002-bib-0005){ref-type="ref"}, [11](#acn351002-bib-0011){ref-type="ref"}, [12](#acn351002-bib-0012){ref-type="ref"}, [13](#acn351002-bib-0013){ref-type="ref"}, [14](#acn351002-bib-0014){ref-type="ref"} This highlights that in many instances the definitive diagnosis relies on finding the causative pathogenic variant(s).[16](#acn351002-bib-0016){ref-type="ref"}

Use of a single panel processed through one reference center (Diagnostic Genomics) for Australasia provided a central data collection point, which facilitated the curation of variants, improving variant interpretation. Weekly interdisciplinary meetings between the clinical, scientific, neuropathological, and research teams were vital for maximizing diagnostic success and triage of unsolved patients to research projects, as reported by others.[10](#acn351002-bib-0010){ref-type="ref"}, [20](#acn351002-bib-0020){ref-type="ref"}, [21](#acn351002-bib-0021){ref-type="ref"} This process facilitated the discovery of six new disease genes.[22](#acn351002-bib-0022){ref-type="ref"}, [23](#acn351002-bib-0023){ref-type="ref"}, [24](#acn351002-bib-0024){ref-type="ref"}, [25](#acn351002-bib-0025){ref-type="ref"}, [26](#acn351002-bib-0026){ref-type="ref"}, [27](#acn351002-bib-0027){ref-type="ref"}

Use of a large panel, rather than exome sequencing, provided the optimal balance between cost and diagnostic success. Panel sequencing costs less than exome sequencing and has only 4--11% lower success rates than exomes restricted to known genes.[18](#acn351002-bib-0018){ref-type="ref"}, [21](#acn351002-bib-0021){ref-type="ref"}, [28](#acn351002-bib-0028){ref-type="ref"} Although panel data cannot be immediately interrogated for new disease genes, we update the panel approximately every 18 months. The panel also allowed higher read‐depth per sample, compared to exome sequencing at the time. The panel provided 309‐fold read‐depth per sample, with 96% of targets covered to \>20‐fold depth. In contrast, our previous experience with SOLiD 5500XL[29](#acn351002-bib-0029){ref-type="ref"} sequencing offered only 66‐fold read‐depth and 84% coverage at 20‐fold or greater depth. The higher read‐depth facilitated CNV detection, and detection of variants within the triplicated regions of *TTN* and *NEB* without need for an additional Comparative Genomic Hybridisation array*.* [30](#acn351002-bib-0030){ref-type="ref"}, [31](#acn351002-bib-0031){ref-type="ref"} Within our study, 4% of genetically diagnosed probands harbored a CNV. Although megabase scale CNVs may have been detected by aCGH, the others are likely too small to be detected. Thus the panel is better equipped to detect CNVs, without the extra cost of running a second test. NGS‐based testing reduces time, cost, and invasive testing compared to the traditional diagnostic work‐up.[21](#acn351002-bib-0021){ref-type="ref"}, [32](#acn351002-bib-0032){ref-type="ref"} We and others recommend a "sequence early" approach, as rapid diagnosis offers the greatest opportunity to influence patient outcomes.[32](#acn351002-bib-0032){ref-type="ref"}, [33](#acn351002-bib-0033){ref-type="ref"}

The diagnostic success of NGS is linked to the cohort inclusion criteria stringency; lower stringency leads to lower diagnostic success.[19](#acn351002-bib-0019){ref-type="ref"} We did not implement strict inclusion criteria. The success rate from our "catch‐all" cohort is in keeping with similar studies[10](#acn351002-bib-0010){ref-type="ref"}, [18](#acn351002-bib-0018){ref-type="ref"}, likely reflecting the experience of other diagnostic centers.[15](#acn351002-bib-0015){ref-type="ref"}

Diagnostic success was negatively correlated with PAR. Other cohorts have displayed enrichment of diagnoses in patients \<18 years.[31](#acn351002-bib-0031){ref-type="ref"}, [34](#acn351002-bib-0034){ref-type="ref"}, [35](#acn351002-bib-0035){ref-type="ref"} The higher diagnostic success in patients \<18 years, especially infants in intensive care, suggests that later‐onset diseases may be more likely to have a polygenic and/or nongenetic etiology (e.g., diabetes causing a peripheral neuropathy).[15](#acn351002-bib-0015){ref-type="ref"}, [36](#acn351002-bib-0036){ref-type="ref"}, [37](#acn351002-bib-0037){ref-type="ref"}

There was a statistically significant decline in diagnostic success on Version 2. Many of the cases analyzed on Version 1 were archived, unsolved samples from Diagnostic Genomics. These samples likely boosted the Version 1 success rate, as they were from well‐phenotyped patients. Therefore, the diagnostic success rate on Version 2 may better reflect the outcome for a truly prospective cohort. Research cases showed a sharp decrease in diagnostic success on Version 2. We suspect this was due to researchers using the panel to exclude known disease genes in patients suspected to have a novel disease gene, based on clinical presentation. In contrast, the diagnostic success rate for AHC diseases increased \~400% (8% to 33%, *n* = 3/37 and *n* = 15/45, *P* = 0.006) from Version 1 to Version 2. The addition of new genes on Version 2 resulted in the diagnosis of only one patient who was clinically described to have AHC disease (*SLC52A2*). Over half of the AHC genetic diagnoses were in genes not typically associated with AHC disease (i.e., *DNM2, FRKP, LAMA2, RYR1, SPAST, SPG11*, *SYNE1*). We suspect the dramatic increase in diagnostic success was due to the recognition that other conditions can mimic AHC diseases.

The overall clinical correlation was 74%, similar to a recent study.[10](#acn351002-bib-0010){ref-type="ref"} The stated clinical diagnosis and the genetic diagnosis were only considered to match if the genotype/phenotype correlation was known at the time of analysis. Disease groupings with low clinical correlation may be especially challenging to diagnose clinically, or the full phenotypic spectrum is yet to be fully realized (e.g., AHC diseases). Conversely, diseases with high clinical correlation (e.g., HSP) may show more specific features that make them easier to diagnose clinically. Experience of the specific disease and the clinical acumen of the referring clinicians also likely contribute to clinical correlation.[10](#acn351002-bib-0010){ref-type="ref"}

The 10 most frequently reported genes were responsible for 38% of diagnoses. These included some of the largest genes (i.e., *DMD, NEB*, *RYR1*, *TTN*), which were unfeasible to sequence pre‐NGS due to their size.[37](#acn351002-bib-0037){ref-type="ref"} Now, their contribution to neuromuscular disease burden and their full phenotypic spectra are being uncovered. For example, *TTN* was a top contributor to congenital myopathy, equal second with *ACTA1* and *NEB* (14%). This aligns with recent findings describing "congenital titinopathy" as a common form of congenital myopathy.[38](#acn351002-bib-0038){ref-type="ref"} [A]{.ul}utosomal [r]{.ul}ecessive [s]{.ul}pastic [a]{.ul}taxia of [C]{.ul}harlevoix‐[S]{.ul}aguenay (ARSACS) was relatively common in our cohort (*n* = 10). ARSACS was initially thought to be primarily a French‐Canadian disease, but has been reported in other populations,[39](#acn351002-bib-0039){ref-type="ref"} and now in Australia.

The percentage of AD pathogenic variants in our cohort (46.3%) is similar to a recently reported Chinese cohort (53%).[10](#acn351002-bib-0010){ref-type="ref"} In contrast, a Saudi population enriched for consanguinity showed 24% of AD pathogenic variants.[18](#acn351002-bib-0018){ref-type="ref"} The relatively high level of AD pathogenic variants in the Australian and Chinese cohorts likely reflects the low level of consanguinity in these populations. Over 60% of the pathogenic variants reported from the panels were nonrecurrent. Recurring variants were known to be common in people of European descent, reflecting the European ancestry of many Australians.[40](#acn351002-bib-0040){ref-type="ref"}, [41](#acn351002-bib-0041){ref-type="ref"}, [42](#acn351002-bib-0042){ref-type="ref"}, [43](#acn351002-bib-0043){ref-type="ref"}, [44](#acn351002-bib-0044){ref-type="ref"}, [45](#acn351002-bib-0045){ref-type="ref"}, [46](#acn351002-bib-0046){ref-type="ref"}, [47](#acn351002-bib-0047){ref-type="ref"}, [48](#acn351002-bib-0048){ref-type="ref"}, [49](#acn351002-bib-0049){ref-type="ref"}, [50](#acn351002-bib-0050){ref-type="ref"} The *SPG7* p.Ala510Val pathogenic variant was by far the most common in our cohort, comprising 4% of all disease alleles.[50](#acn351002-bib-0050){ref-type="ref"}

In conclusion, targeted neuromuscular disease panels in an Australasian referral center resulted in a genetic diagnosis of 665 patients. The causative variant(s) were often unexpected based on the clinical details provided; thus we believe smaller disease‐specific panels would have been less effective. We identified several novel variants and genotype--phenotype expansions. The panels enabled the research team to focus on genetically undiagnosed patients that were likely to harbor variants in novel disease genes. A key advantage of a centralized referral center is the ability to better classify VUS based on their aggregate data. Collaboration between the diagnostic facility and clinical team can be vital for reaching a definitive genetic diagnosis. We recommend a centralized approach for genetic diagnosis of neuromuscular diseases and the use of comprehensive targeted gene panels.
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